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Every year, 33,700 new cases of cancer are diagnosed in 
Catalonia; and one in two men and one in three women will 
develop cancer in their lifetime. Consequently, cancer is a 
very important health issue with serious financial implica­
tions. In the period 2001–2007, the number of cancer­asso­
ciated deaths decreased by only 1.3–1.4 % and the 5­year 
survival rates have not been optimistic either: 51 % for men 
and 63 % for women. The slightly higher rate for women 
mainly reflects the fact that survival rates for breast cancer 
patients are around 83 % because of good management of 
this type of cancer, which is often detected at very early 
stages. But there are also tumours for which the outcome of 
affected patients is dismal, such as small­cell lung cancer (5­
year survival rate of 14 %). 
Why has there been much less progress in treating lung and 
pancreatic cancers than breast cancer? Are there differences 
in the biology of these tumours? Is it only because of the earlier 
detection of breast cancer? We are not going to be able to get 
answers to these questions by random chance, nor is a single 
discovery in a small lab likely to cure cancer. Instead, a sus­
tained effort is needed over many years, aided by the European 
Union in bringing together the best scientists around the world 
to tackle the problem.
If we look at different types of cancer in Catalonia (2003–
2007, Fig. 1), we observe that the incidence of cancer is very 
similar to that in the rest of Europe: in men, prostate, lung and 
colon cancers are the most common malignancies. In wom­
en, breast cancer is the most frequent, but lung cancer is in­
creasing, as women started smoking later such that only now 
is the peak of what is expected to be a massive incidence of 
lung cancer occurring. 
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Resum. La medicina personalitzada significa trobar el tracta­
ment adequat per al pacient adequat en el moment adequat. 
Per bé que aquesta és una idea molt global i molt simple, és 
molt difícil d’aconseguir. Fer­ho requereix un esforç conjunt 
dels professionals de tots els àmbits: científics, polítics, advo­
cats, economistes, etcètera, així com de sinergies entre investi­
gadors, companyies farmacèutiques i biotecnològiques, i entre 
el sector públic i el privat. En la medicina personalitzada del 
càncer, un tumor s’analitza segons la genòmica, genètica, epi­
genòmica, característiques cel·lulars i bioquímiques que té, i se 
cerca la baula més feble per a millorar la probabilitat que el paci­
ent respongui bé a la teràpia escollida. Els nombrosos avantat­
ges d’aquest enfocament fan que sigui crucial per a donar su­
port a la investigació que conduirà al descobriment de nous 
biomarcadors, capaços de predir la sensibilitat d’un pacient als 
medicaments, per al seu ús en la medicina personalitzada. 
Paraules clau: medicina personalitzada ∙ epigenètica ∙ 
epigenòmica ∙ càncer ∙ metilació del DNA ∙ biomarcadors ∙ 
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Summary. Personalised medicine means finding the right 
treatment for the right patient at the right time. Although this is 
a very global, very simple idea, it is nonetheless very difficult to 
achieve. To do so requires a concerted effort from profession­
als in all fields: scientists, politicians, lawyers, economists, etc., 
as well as synergies between researchers, pharmaceutical and 
biotech companies, and between the public and private sec­
tors. In personalised cancer medicine, a tumour is analysed ac­
cording to its genomics, genetics, epigenetics, epigenomics, 
cellular features, and biochemistry, and searches for its weak­
est link in order to improve the likelihood that the patient will 
respond to the therapy chosen accordingly. The numerous ad­
vantages of this approach make it crucial to support the re­
search that will lead to the discovery of new biomarkers ,capa­
ble of predicting a patient’s sensitivity to drugs, for their use in 
personalised medicine. 
Keywords: personalised medicine ∙ epigenetics ∙ 
epigenomics ∙ cancer ∙ DNA methylation ∙ biomarkers ∙ MGMT 
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* Based on the lecture given by the author at the Parliament of Catalo­
nia, Barcelona, on 23 October 2012 for the annual conference of the 
EPTA network, ‘From genes to jeans: challenges on the road to per­
sonalised medicine.’
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Personalised medicine in the treatment of cancer
What is the role of personalised medicine in the treatment of 
cancer? It is finding the right treatment for the right patient at 
the right time. Although this is a very global, very simple idea, it 
is nonetheless very difficult to achieve. To do so requires a con­
certed effort from professionals in all fields: scientists, politi­
cians, lawyers, economists, etc. Personalised medicine is like 
finding the Achilles heel, the weakest point, in the disease 
process. In conventional therapy, if a person has a tumour, the 
oncologist or the pathologist will analyze a biopsy under the 
optical microscope. 
But if the patient’s tumour exhibits all the features of another 
patient’s tumour, the same treatment will be administered for 
the same clinical stage, although the two patients may com­
pletely differ in their therapeutic responses. This is because the 
cellular and molecular repertoires of the tumours may be com­
pletely distinct, reflecting different genetic alterations. Person­
alised medicine, by contrast, considers a tumour according to 
its genomics, genetics, epigenetics, epigenomics, cellular fea­
tures, and biochemistry, and searches for its weakest link in 
any one in order to improve the likelihood that the patient will 
respond to the therapy chosen accordingly.
There are many advantages to this approach, but first and 
foremost is the fact that patients receive the right treatment for 
the right tumour; second, the use of ineffectual therapies is 
avoided, which reduces healthcare costs and spares non­re­
sponding patients unnecessary toxicity while improving his or 
her quality of life.
“One dumb tumour is smarter than 100 
oncologists”
This anonymous sentence appeared on the web a few years 
ago, but unfortunately it remains true today. The combined ef­
forts of 100 oncologists cannot cure 80–90 % of lung tumours. 
Cancer is a complex disease that requires intense research ef­
forts and investment. But there is light at the end of the tunnel. 
If we look at the genetics of cancer, what we have is a handful 
of biomarkers that predict which drug the patient’s tumour 
should be more sensitive to. Moreover, there may be five/six 
genetic mutations targeted by five/six approved drugs to which 
patients are likely to respond. But this is just the tip of the ice­
berg and much more research is needed before a complete 
therapeutic picture is obtained for each and every patient.
Our lab, like many labs around the world, is studying an­
other aspect of cancer: epigenetics. Epigenetics considers 
DNA as a part of the story, but not the whole story. For exam­
ple, all our cells contain the same DNA, but neurons look very 
different from muscle cells. This is because different chemical 
markers regulate the expression of genes, including those re­
sponsible for switching­on and switching­off other genes. 
These markers may consist of DNA­methylation, histomodifi­
cations, etc. and they are responsible for producing different 
cellular phenotypes. Thus, in monozygotic (identical) twins, 
even though their DNA is the same, one twin may develop 
breast cancer at age 25 and the other at age 65, because of 
epigenetic differences. In one twin the gene in question may 
be methylated, and in the other unmethylated [7]. 
Since the difference in control of the gene is chemical and 
does not involve sequences, it will not be detected by se­
quencing. In the words of Francis Collins, director of the US 
National Institutes of Health (NIH), “here is something where 
Mendel, Watson and Crick all seem to have missed some cru­
cial goodies.” Methylation can be imagined like a traffic signal, 
blocking the expression of some genes and enhancing the ex­
pression of others. At the moment we are studying these 
changes in DNA methylation and the genes that are altered in 
cancer only by DNA methylation. Some of this knowledge has 
reached clinical stages.
From single epigenetic biomarkers to 
epigenomics
As an example of therapy prediction in personalised cancer 
medicine, take the example of a particular marker, MGMT. Im­
agine that a patient goes to the doctor, who finds a tumour that 
is already metastatic. The doctor is unable to say what type of 
Fig. 1. Cancer incidence in Catalonia (2003–2007): The ten most common tumour types.
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tumour it is, where it came from, and therefore what the appro­
priate therapy is. But what if we could take a picture or obtain a 
fingerprint and compare it to a collection of pictures/finger­
prints of known tumours? This would allow us to determine 
whether the patient’s tumour resembles breast cancer, colon 
cancer, a brain tumour, etc. (Fig. 2) [8,9]
The tumour marker MGMT provides us exactly with this infor­
mation, in the form of a DNA methylation profile of a tumour sam­
ple analyzed for this tumour marker—and this offers a strategy 
for many of the markers we know. Accordingly, further research, 
diagnostic development, and clinical trials will require synergies 
between academics, researchers, pharmaceutical and biotech 
companies, and between the public and private sectors. 
MGMT is a gene that codes for a DNA repair enzyme, and 
we discovered that the respective gene is silenced—methylat­
ed—in cancer. We made this discovery in 1999, before the 
‘­omics’ revolution, by looking at candidate genes one by one 
and realizing that the MGMT gene is methylated in gliomas, 
which are tumours that start in the brain or spine. In its methyl­
ated state, MGMT cannot repair damaged DNA, such that tu­
mours with methylated MGMT have more mutations and are 
more aggressive [3] We showed that gliomas with MGMT 
methylation are more sensitive to the family of drugs that in­
cludes procarbazine, dacarbazine, BCNU, and ACNU, be­
cause they target the same site in the DNA [4].
Ten years later, in 2009, in the ‘–omics’ era, we were able 
to address this same issue using a micro­array, which identi­
fied MGMT, the same gene that we had found 10 years be­
fore. In parallel, scientists collaborating in the Cancer Genome 
Atlas Research Network arrived at the same conclusions [1]. 
This research was particularly satisfying because it yielded 
consistent results, with the effect of the MGMT gene validated 
using the new technology. Consequently, genomics seems to 
be a profitable route to finding new biomarkers for use in a 
personalised medicine approach to cancer.
Another example is BRCA1, a breast cancer susceptibility 
gene mapped to chromosome 17q21 by linkage studies. De­
fects in this gene are predicted to be responsible for 45 % of 
inherited breast cancers and >80 % of inherited breast and 
ovarian cancers. However, despite the high incidence of a loss 
of heterozygosity of the BRCA1 region in sporadic breast and 
ovarian cancers, BRCA1 somatic mutations have been found 
only in a few cases of sporadic ovarian and breast cancers. 
This suggests that an alternative mechanism for the inactiva­
tion of BRCA1, or other genes in its vicinity, plays an important 
role in the development of sporadic breast and ovarian can­
cers. Importantly, several labs found that a genetic alteration in 
BRCA1predicts that the tumour cells will be very sensitive to a 
family of drugs called PARP inhibitors [2]. 
While this is great news, the disadvantage is that out of a 
hundred patients with breast or ovarian tumours, only one or 
two will have this mutation, which in turn reveals one of the 
typical problems of personalised medicine: drug approval. The 
problem is actually two­fold, because if the drug is of interest 
for only a few patients, the economic benefits for the company 
that produces it will be too low to justify its production. How 
can we treat small populations of patients such that pharma­
ceutical companies can recover their costs? 
In this particular case, we determined that it is not only the 
mutation but also the methylation state of the gene that pre­
dicts DNA damage and therefore the response to the drug. If 
25 out of 100 breast cancer patients can be identified as re­
sponders, in this case to PARP inhibitors, the production of this 
drug may be justified, by introducing the right biomarker [5,6]. 
Thus, in clinical trials, the inclusion of biomarkers is critical be­
cause they will encourage the approval of effective drugs. 
Moreover, there are also many effective drugs from the past 
that can be rescued, if they are administered to patients tested 
Fig. 2. Methylation Specific 
PCR (MSP) of MGMT. ‘U’ in­
dicates the presence of un­
methylated genes of MGMT; 
‘M’ indicated the presence of 
methylated genes. (A) Normal 
Tissue. IVD: in vitro methylat­
ed DNA as positive control for 
methylation; H20: water con­
trol for PCR. (B) Cancer cell 
lines. (C) Primary gliomas. (D) 
Colorectal carcinoma. (E) 
Lung carcinoma. (F) Primary 
lymphomas. Source: [3]].
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for the appropriate biomarkers.
Nowadays, we can use micro­arrays to obtain a complete 
DNA methylation fingerprint of any tumour. Over 20 methylated 
genes predict the responses to different chemotherapy drugs 
[12]. At the moment, however, only one such gene, MGMT, 
has been approved in Europe, to stratify patients with glioma. 
Other marker genes await approval for different reasons, e.g., 
they are very new, discovered in the last month, the last year, 
or the last 2 years. But in other cases there is insufficient inter­
est on the part of pharmaceutical companies in their diagnostic 
development and other sources of investment are lacking. In 
the latter case, investment must come from the public arena, 
especially the European Union.
Thus, research leading to the discovery of new biomarkers 
for use in a personalised medicine approach to cancer must 
be supported. For example, the project called ‘Curelung,’ 
[www.curelung.eu] coordinated from our lab in Barcelona, 
has been funded in its totality by the FP7 program of the Eu­
ropean Union. Its aim is to find biomarkers that predict the 
response to chemotherapy in lung cancer, which is still the 
most lethal type of cancer worldwide and specifically in Eu­
rope, where it accounts for 12.3 % of all new cancer cases 
every year. As noted in the first paragraphs of this article, lung 
cancer patients have a very poor prognosis, with a 5­year 
survival of only 14 %. One of the objectives of the project is to 
define the epigenetic markers that could determine the effi­
cacy of or resistance to targeted therapies. Preliminary results 
indicate the stratification of lung tumours according to their 
genetic background, which translates into improved patient 
selection. We now have the technology not only to sequence 
complete genomes, but also to obtain complete epigenomes, 
complete methilomes. In 5 years we will probably be able to 
understand much of the data generated in these types of 
analyses.
Final considerations on personalised cancer 
medicine
To end this discussion on personalised medicine in the treat­
ment of cancer, I would like to offer five considerations. First, 
is the need to keep in mind that tumours are heterogeneous. 
This means that even within a tumour there are small popula­
tions of cells that differ from the majority. Thus, even if we 
have a good biomarker for, say, 90 % of the cells, the remain­
ing 10 % will be different and are likely to be the source of a 
relapse, with reappearance of the tumour. The answer is 
likely to be personalised cancer therapy that differs accord­
ing to disease stage: primary tumour, metastasis, relapse, 
etc. Second, it is important that good drugs, both new and 
recycled, receive timely approval and that all clinical trials in­
clude the use of a biomarker, if at all possible. Very good 
drugs are already available. But if they are given to all patients 
at the same disease stage, their true benefit may not be ap­
preciated. However, if biomarkers predict the efficacy of the 
drug for the cancer stage of a particular patient, even if the 
drug is an older one he or she should receive it, even if it is no 
longer under patent protection or its continued manufacture 
is not financially profitable for the drug company. Third, we 
must stop using inefficient drugs. For example, some recent­
ly approved drugs increase survival by only 3 weeks—can 
this truly be claimed as a statistically significant effect? As a 
scientist, I do not see the benefit from their continued use. 
And yet these drugs have been approved. Fourth, it is crucial 
to avoid toxicity to respect the quality of life of cancer pa­
tients. Some of the drugs used in cancer treatment are not 
only of extremely limited efficacy, they are highly toxic. Some 
patients prefer a shorter survival but one that offers a higher 
quality of life, allowing them to spend time with friends and 
family and to avoid unnecessary financial burdens. This deci­
sion must be honoured. 
Personalised cancer medicine also translates into cost sav­
ings for the healthcare industry as it can avoid useless treat­
ment while freeing up resources for those patients likely to re­
spond. Pathologists, for example, often ask me, “How can I 
convince my hospital director to implement personalised can­
cer medicine in my hospital?” The use of IT and cost­benefit 
analyses are powerful tools for convincing hospitals that per­
sonalised medicine is not the way of the future; it should be 
implemented now.
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